The company was founded in 2003 to embody our mission to develop cutting-edge treatments to devastating illnesses that threaten patients’ lives. We are developing treatments for arthritis, cardiovascular disease, stroke, and cancer because no matter where you look, people are suffering from these diseases that currently have no cure.

Our scientists come from leading healthcare research institutions such as Case Western Reserve University and The Cleveland Clinic Foundation; and they are dedicated to creating world-class drugs and developing cutting edge technologies to meet the new century’s most pressing medical needs. NovelMed’s approach is to develop target specific monoclonal antibodies and small molecule therapies to provide maximum benefit to patients suffering from such diseases. NovelMed’s goal is to provide therapies to improve quality of patient’s life where no such treatments are available.

NovelMed’s products treat disease conditions by targeting a disease at the root of the problem through the use on target-specific monoclonal antibodies. Therapeutic monoclonal antibodies are unique because they bind a specific target and neutralizes its function which is apparently responsible for the disease in question. NovelMed has also developed small molecule therapies to provide treatments for multi-etiological disease such as arthritis. Using these two therapeutic approaches, NovelMed has developed a pipeline of products that will ensure maximum therapeutic benefit with the least amount of adverse effects. These therapeutic drugs have been crafted into cutting-edge therapies with utmost care.

NovelMed’s therapeutic development efforts are built on a solid foundation of intellectual property. Our scientists have been filing patent applications for discoveries since our company’s inception. Securing intellectual property for our technologies and discoveries is essential to NovelMed’s growth and success. Our success will result in the availability of “novel therapeutics” where no such therapy existed before proving once again that NovelMed continues to secure leadership in such areas.

Well-equipped research facilities are essential to the discovery process; and our laboratory is fully outfitted to research and develop "novel therapeutics" for arthritis, cardiovascular disease, stroke, and cancer. NovelMed is located in the BioEnterprise Building (www.bioenterprise.com) in Cleveland, Ohio. BioEnterprise serves as an incubator for biotechnology companies and provides business support to develop relationships with investors and other pharmaceutical companies. We are within walking distance of world-class institutions such as The Cleveland Clinic Foundation, University Hospitals of Cleveland, Rainbow Babies and Children's Hospital, and Case Western Reserve University. Such close proximity allows NovelMed to share significant resources at minimal cost, which has fostered the company’s growth.

By far the most important of all is the strength is our scientists, collaborators, consultants, and management and business advisors who continue to provide support to NovelMed. Current team consists of biochemists, molecular biologists, chemists, medicinal chemists, experts in inflammation-cardiovascular-thrombosis-cancer, FDA-regulatory, and business advisors. Looking ahead, NovelMed is poised to continue on its path to success and develop treatments that promote patient quality of life. To do this, we continue to build our intellectual property portfolio and shepherd our discoveries through the drug approval process to market.